{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 461093150
| IUPAC_name = 3'-{(2''Z'')-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4''H''-pyrazol-4-ylidene]hydrazino}-2'-hydroxy-3-biphenylcarboxylic acid
| image = eltrombopag.svg
| width = 270

<!--Clinical data-->
| tradename = Promacta, Revolade
| Drugs.com = {{drugs.com|monograph|eltrombopag}}
| MedlinePlus = a609011
| licence_EU = Revolade
| licence_US = Eltrombopag
| pregnancy_AU = B3
| pregnancy_US = C
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| legal_US = Rx Only <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = 
| dependency_liability = 
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability = ~52%<ref>{{cite web|title=Promacta<sup>®</sup> (eltrombopag) Tablets, for Oral Use and for Oral Suspension. Full Prescribing Information|url=http://www.pharma.us.novartis.com/product/pi/pdf/promacta.pdf|publisher=GlaxoSmithKline, Research Triangle Park, NC 27709|accessdate=13 September 2015}}</ref>
| protein_bound = >99%
| metabolism = extensive [[Liver|hepatic]] (through [[CYP1A2]] and [[CYP2C8]]
| elimination_half-life = 21–35 hours
| excretion = feces (59%), urine (31%)

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 496775-61-2
| CAS_supplemental = <br />{{CAS|496775-62-3}} ([[olamine]])
| ATC_prefix = B02
| ATC_suffix = BX05
| ATC_supplemental =  
| PubChem = 9846180
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 21106301
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = S56D65XJ9G
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 461101

<!--Chemical data-->
| C=25 | H=22 | N=4 | O=4 
| molecular_weight = 442.467 g/mol
| smiles = CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)NN=C3C=CC=C(C3=O)C4=CC(=CC=C4)C(=O)O)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C25H22N4O4/c1-14-10-11-19(12-15(14)2)29-24(31)22(16(3)28-29)27-26-21-9-5-8-20(23(21)30)17-6-4-7-18(13-17)25(32)33/h4-13,26,30H,1-3H3,(H,32,33)/b27-22+
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = XDXWLKQMMKQXPV-HPNDGRJYSA-N
}}

'''Eltrombopag''' ([[International Nonproprietary Name|rINN]], codenamed SB-497115-GR) is a [[medication]] that has been developed for certain conditions that lead to [[thrombocytopenia]] (abnormally low [[platelet]] counts). It is a small molecule [[agonist]] of the [[c-mpl]] (TpoR) [[receptor (biochemistry)|receptor]], which is the physiological target of the [[hormone]] [[thrombopoietin]]. Eltrombopag was discovered as a result of research collaboration between [[GlaxoSmithKline]] and [[Ligand Pharmaceuticals]]. Designated an [[orphan drug]] in the United States and [[European Union]], it is being manufactured and marketed by [[GlaxoSmithKline]] under the trade name '''Promacta''' in the USA and is marketed as '''Revolade''' in the EU.

==Approvals and indications==
Eltrombopag was initially approved by the [[U.S. Food and Drug Administration]] on November 20, 2008, for the treatment of thrombocytopenia in patients with chronic [[immune thrombocytopenic purpura|immune (idiopathic) thrombocytopenic purpura]] who have had an insufficient response to [[corticosteroids]], [[immunoglobulin therapy]], or [[splenectomy]].<ref>{{cite web|title=Approval Letter|url=http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/022291s000ltr.pdf|website=fda.gov|publisher=United States Food and Drug Administration|accessdate=18 March 2016}}</ref>

Eltrombopag received FDA [[breakthrough therapy|breakthrough treatment]] designation in February 2014 for patients with [[aplastic anemia]] for which immunosuppression has not been successful.<ref>{{cite web|title=Eltrombopag / Promacta|url=http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm459467.htm|website=fda.gov|publisher=United States Food and Drug Administration|accessdate=18 March 2016}}</ref>  In 2017, the NIH made Eltrombopag a standard of care in aplastic anemia.<ref>{{Cite journal|last=Townsley|first=Danielle M.|last2=Scheinberg|first2=Phillip|last3=Winkler|first3=Thomas|last4=Desmond|first4=Ronan|last5=Dumitriu|first5=Bogdan|last6=Rios|first6=Olga|last7=Weinstein|first7=Barbara|last8=Valdez|first8=Janet|last9=Lotter|first9=Jennifer|date=2017-04-20|title=Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia|url=http://dx.doi.org/10.1056/NEJMoa1613878|journal=New England Journal of Medicine|volume=376|issue=16|pages=1540–1550|doi=10.1056/NEJMoa1613878|issn=0028-4793|pmid=28423296}}</ref>  It has been shown to produce a trilineage hematopoesis in some patients with aplastic anemia, resulting in increased platelet counts, along with red and white blood cell counts.<ref>{{cite journal|vauthors=Desmond R, Townsley DM, Dumitriu B, Olnes MJ, Scheinberg P, Bevans M, Parikh AR, Broder K, Calvo KR, Wu CO, Young NS, Dunbar CE|title=Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug|journal=Blood|volume=123|issue=12|pages=1818–25|date=March 2014|pmid=24345753|doi=10.1182/blood-2013-10-534743|url = http://bloodjournal.hematologylibrary.org/content/123/12/1818.long?hw-tma-check=true}}</ref>

On August 24, 2015, the FDA approved eltrombopag (Promacta for oral suspension) for the treatment of thrombocytopenia in pediatric patients 1 year and older with idiopathic thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.<ref>{{cite web|title=FDA extends use of Promacta in young children with rare blood disorder|url=http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm459430.htm|website=fda.gov|publisher=United States Food and Drug Administration|accessdate=18 March 2016}}</ref>

==Development==
In [[Phase III trials#Pre-clinical studies|preclinical studies]], the compound was shown to interact selectively with the thrombopoietin receptor, leading to activation of the [[JAK-STAT signaling pathway]] and increased proliferation and differentiation of [[megakaryocyte]]s. Animal studies confirmed that it increased platelet counts. In 73 healthy volunteers, higher doses of eltrombopag caused larger increases in the number of circulating platelets without tolerability problems.<ref name=Jenkins>{{cite journal|vauthors = Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D, Erickson-Miller CL|title=Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist|journal=Blood|volume=109|issue=11|pages=4739–41|date=June 2007|pmid=17327409|doi = 10.1182/blood-2006-11-057968|url=http://bloodjournal.hematologylibrary.org/cgi/content/full/109/11/4739 }}</ref>

==Clinical trials==
Eltrombopag has been shown to be effective in two major clinical syndromes: [[idiopathic thrombocytopenic purpura]]<ref>{{cite journal|vauthors=Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, Arning M, Provan D, Jenkins JM|title=Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura|journal=The New England Journal of Medicine|volume=357|issue=22|pages=2237–2247|date=November 29, 2007|pmid=18046028|doi= 10.1056/NEJMoa073275}}</ref> and [[cirrhosis]] due to [[hepatitis C]] (in which low platelet counts may be a contraindication for [[interferon]] treatment).<ref>{{cite journal|vauthors=McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon SC, Campbell FM, Theodore D, Blackman N, Jenkins J, Afdhal NH|title=Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C|journal=The New England Journal of Medicine|volume=357|issue=22|pages=2227–2236|date=November 29, 2007|pmid=18046027|doi = 10.1056/NEJMoa073255 }}</ref>

After 6 weeks of therapy in a [[Phase III trials#Phase III|phase III trial]], eltrombopag 50&nbsp;mg/day was associated with a significantly higher response rate than placebo in adult patients with chronic ITP.<ref name="pmid19368418">{{cite journal|vauthors=Garnock-Jones KP, Keam SJ|title=Eltrombopag|journal=Drugs|volume=69|issue=5|pages=567–76|year=2009|pmid=19368418|doi=10.2165/00003495-200969050-00005 }}</ref>

== References ==
{{reflist|33em}}

{{Antihemorrhagics}}
{{Cytokine receptor modulators}}
{{GlaxoSmithKline}}

[[Category:Drugs acting on the blood and blood forming organs]]
[[Category:Orphan drugs]]
[[Category:Biphenyls]]
[[Category:Hydrazines]]
[[Category:Breakthrough therapy]]
[[Category:Carboxylic acids]]